<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01887990</url>
  </required_header>
  <id_info>
    <org_study_id>F120307001</org_study_id>
    <nct_id>NCT01887990</nct_id>
  </id_info>
  <brief_title>Treatment of Suicidal Ideation With Intravenous Ketamine Infusion</brief_title>
  <official_title>Treatment of Suicidal Ideation With Intravenous Ketamine Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is dedicated to achieving better treatments for suicidal thoughts. Specifically,
      the investigators are studying the effect of a medication called ketamine to quickly treat
      suicidal thoughts and depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is dedicated to achieving better treatments for suicidal thoughts. Specifically,
      we are studying the effect of a medication called ketamine to quickly treat suicidal thoughts
      and depression. Patients will be asked to participate in a research study to study how the
      use of a medication, ketamine, decreases your suicidal thoughts and improves their symptoms
      of depression. Ketamine is approved by FDA for use at higher doses in anesthesia, and recent
      clinical research suggests that it might benefit patients with major depressive disorder and
      suicidal thoughts. During clinical trials with over 10,000 patients, ketamine was proved to
      be safe as an anesthetic and studies with hundreds of patients with depression have
      demonstrated safety and lack of lasting side effects. This is a pilot study to test a new use
      of ketamine: treatment of suicidal thoughts. The study medication will be given in addition
      to usual psychiatric care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Suicidality</measure>
    <time_frame>2 hours</time_frame>
    <description>Scales and questionnaires using the Beck Scale for Suicidal Ideation. The Beck Scale is a self-report questionnaire. The items on this scale identify the presence and severity of suicidal ideation.
Beck Scale for Suicidal Ideation has 19 items,preceded by a 5 item screener. Each item is rated on a 3 point scale from 0 to 2. Scores range from 0 to 48. Total scoreScores of 0 - 16 indicate low risk for suicide; scores of 16 or greater indicate higher risk for suicide.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>2 hours</time_frame>
    <description>Scales and Questionnaire using the MADRS (Montgomery-Asberg Depression Rating Scale) . This is a ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. the scale: 0 - 6 (normal/symptom absent), 7 - 19 (mild depression), 20 - 34 (moderate depression), and &gt; 34 (severe depression).The overall score ranges from 0 to 60</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Depression</condition>
  <condition>Suicidal Ideation</condition>
  <arm_group>
    <arm_group_label>Suicidal, Depression with Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>suicidal ideation and depression (no substance use disorder) 0.2 mg/kg IV ketamine administered as a one time dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suicidal, Depression with Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Suicidal ideation and depression (no substance use disorder) comparable amount of placebo (saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suicidal, opioid use with ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>suicidal ideation,depression, opioid use disorder 0.2 mg/kg IV ketamine one time dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suicidal, opioid use with Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with suicidal ideation and depression with opioid use disorder who are given comparable amount of placebo (saline) as would have been used with the Ketamine arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>single dose IV 0.2 mg/kg ketamine</description>
    <arm_group_label>Suicidal, Depression with Ketamine</arm_group_label>
    <arm_group_label>Suicidal, opioid use with ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>saline infusion</description>
    <arm_group_label>Suicidal, Depression with Saline</arm_group_label>
    <arm_group_label>Suicidal, opioid use with Saline</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age : 19-64

          2. Significant suicidality score on the Columbia Suicide Severity Rating Scale (C-SSRS)

          3. Willing and able to provide informed consent.

          4. Individuals with current substance abuse are allowed

        Exclusion Criteria:

          1. Pregnant or lactating; women of reproductive potential must have a negative urine
             pregnancy test (urine dipstick method)

          2. Post-Partum state : defined as being within 2 months of delivery or miscarriage

          3. Homicide risk as determined by clinical interview

          4. Treatment with any medication known to specifically target the glutamate-NMDA receptor
             system (ie lamotrigine, acamprosate, memantine, riluzole or lithium)

          5. Any known hypersensitivity or serious adverse effect associated with ketamine
             treatment.

          6. Any clinically significant medical condition or therapy that would preclude treatment
             with ketamine, to include recent myocardial infarction or unstable angina

          7. Medically unstable, including acute withdrawal from alcohol or benzodiazepines
             requiring the use of benzodiazepine treatment.

          8. Any of the following DSM-IV diagnoses or categories:

               -  Any current psychosis or history of a non-mood psychotic disorder (e.g.,
                  schizophrenia)

               -  Currently in a manic or mixed episode

               -  Current use (defined by urine dipstick test) or abuse of hallucinogenic drugs
                  (except marijuana) such as phencyclidine

               -  Any dissociative disorder

               -  Any pervasive developmental disorder (e.g., autism)

               -  A cognitive disorder (e.g., Alzheimer's Disease)

               -  Cluster A personality disorder (e.g., schizoid or schizotypal); note that cluster
                  B and C personality disorders may be included

               -  Any eating disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheryl B McCullumsmith, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2013</study_first_posted>
  <results_first_submitted>November 21, 2014</results_first_submitted>
  <results_first_submitted_qc>June 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2015</results_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Dr. Richard Shelton</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suicidal Ideation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Suicidal, Depression With Ketamine</title>
          <description>0.2 mg/kg IV ketamine administered as a one time dose in patients with suicidal ideatin and depression without substance use
Ketamine</description>
        </group>
        <group group_id="P2">
          <title>Suicidal, Depression With Saline</title>
          <description>comparable amount of placebo (saline) as would have been used with the Ketamine arm
placebo</description>
        </group>
        <group group_id="P3">
          <title>Suicidal, Depression and Opioid Use With Ketamine</title>
          <description>suicidal, depressed with opioid use, given 0.2 mg/kg ketamine one time dose IV infusion</description>
        </group>
        <group group_id="P4">
          <title>Suicidal, Depression With Opioid Use With Saline</title>
          <description>suicidal, depression with opioid use, given saline IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Suicidal, Depression With Ketamine</title>
          <description>suicidal and depressed, no substance use 0.2 mg/kg IV ketamine administered as a one time dose
Ketamine</description>
        </group>
        <group group_id="B2">
          <title>Suicidal, Depression With Saline</title>
          <description>suicidal and depressed, no substance use comparable amount of placebo (saline) as would have been used with the Ketamine arm
placebo</description>
        </group>
        <group group_id="B3">
          <title>Suicidal, Depression and Opioid Use With Ketamine</title>
          <description>suicidal and depressed, opioid use 0.2 mg/kg IV ketamine administered as a one time dose
Ketamine</description>
        </group>
        <group group_id="B4">
          <title>Suicidal, Depression and Opioid Use With Ketamine</title>
          <description>suicidal and depressed,opioid use comparable amount of placebo (saline) as would have been used with the Ketamine arm
placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="10"/>
                    <measurement group_id="B2" value="37" spread="11"/>
                    <measurement group_id="B3" value="31" spread="1"/>
                    <measurement group_id="B4" value="31" spread="4"/>
                    <measurement group_id="B5" value="35" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Suicidality</title>
        <description>Scales and questionnaires using the Beck Scale for Suicidal Ideation. The Beck Scale is a self-report questionnaire. The items on this scale identify the presence and severity of suicidal ideation.
Beck Scale for Suicidal Ideation has 19 items,preceded by a 5 item screener. Each item is rated on a 3 point scale from 0 to 2. Scores range from 0 to 48. Total scoreScores of 0 - 16 indicate low risk for suicide; scores of 16 or greater indicate higher risk for suicide.</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Suicidal, Depression With Ketamine</title>
            <description>0.2 mg/kg IV ketamine administered as a one time dose
Ketamine</description>
          </group>
          <group group_id="O2">
            <title>Suicidal, Depression With Saline</title>
            <description>comparable amount of placebo (saline) as would have been used with the Ketamine arm
placebo</description>
          </group>
          <group group_id="O3">
            <title>Suicidal, Opioid Use With Ketamine</title>
            <description>suicidal ideation,depression, opioid use disorder 0.2 mg/kg IV ketamine one time dose</description>
          </group>
          <group group_id="O4">
            <title>Suicidal, Opioid Use With Saline</title>
            <description>Patients with suicidal ideation and depression with opioid use disorder who are given comparable amount of placebo (saline) as would have been used with the Ketamine arm</description>
          </group>
        </group_list>
        <measure>
          <title>Suicidality</title>
          <description>Scales and questionnaires using the Beck Scale for Suicidal Ideation. The Beck Scale is a self-report questionnaire. The items on this scale identify the presence and severity of suicidal ideation.
Beck Scale for Suicidal Ideation has 19 items,preceded by a 5 item screener. Each item is rated on a 3 point scale from 0 to 2. Scores range from 0 to 48. Total scoreScores of 0 - 16 indicate low risk for suicide; scores of 16 or greater indicate higher risk for suicide.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="11.4"/>
                    <measurement group_id="O2" value="21.5" spread="14.7"/>
                    <measurement group_id="O3" value="18.0" spread="25.5"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression</title>
        <description>Scales and Questionnaire using the MADRS (Montgomery-Asberg Depression Rating Scale) . This is a ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. the scale: 0 - 6 (normal/symptom absent), 7 - 19 (mild depression), 20 - 34 (moderate depression), and &gt; 34 (severe depression).The overall score ranges from 0 to 60</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Suicidal, Depression With Ketamine</title>
            <description>0.2 mg/kg IV ketamine administered as a one time dose
Ketamine</description>
          </group>
          <group group_id="O2">
            <title>Suicidal, Depression With Saline</title>
            <description>comparable amount of placebo (saline) as would have been used with the Ketamine arm
placebo</description>
          </group>
          <group group_id="O3">
            <title>Suicidal, Opioid Use With Ketamine</title>
            <description>suicidal pts who have used opioids, in the ketamine treatment arm</description>
          </group>
          <group group_id="O4">
            <title>Suicidal, Opioid Use With Saline</title>
            <description>suicidal patients who use opioids who received saline infusion or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Depression</title>
          <description>Scales and Questionnaire using the MADRS (Montgomery-Asberg Depression Rating Scale) . This is a ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. the scale: 0 - 6 (normal/symptom absent), 7 - 19 (mild depression), 20 - 34 (moderate depression), and &gt; 34 (severe depression).The overall score ranges from 0 to 60</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" spread="26"/>
                    <measurement group_id="O2" value="59.4" spread="17.2"/>
                    <measurement group_id="O3" value="22.5" spread="17.7"/>
                    <measurement group_id="O4" value="12.5" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Suicidal, Depression With Ketamine</title>
          <description>Suicidal with depression and no substance use 0.2 mg/kg IV ketamine administered as a one time dose
Ketamine</description>
        </group>
        <group group_id="E2">
          <title>Suicidal, Depression With Saline</title>
          <description>Suicidal with depression and no substance use comparable amount of placebo (saline) as would have been used with the Ketamine arm
placebo</description>
        </group>
        <group group_id="E3">
          <title>Suicidal, Depression and Opioid Use With Ketamine</title>
          <description>Suicidal with depression and opioid use 0.2 mg/kg IV ketamine administered as a one time dose
Ketamine</description>
        </group>
        <group group_id="E4">
          <title>Suicidal, Depression and Opioid With Saline</title>
          <description>Suicidal with depression and opioid use comparable amount of placebo (saline) as would have been used with the Ketamine arm
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>sedation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>short term followup small sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Cheryl McCullumsmith</name_or_title>
      <organization>University of Cincinnati</organization>
      <phone>513-5588022</phone>
      <email>cheryl.mccullumsmith@uc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

